[1] Deng C, Pan B, Engel M, et al. Neuregulin-1 signalling and antipsychotic treatment: potential therapeutic targets in a schizophrenia candidate signalling pathway[J]. Psychopharmacology (Berl), 2013, 226(2): 201-215. DOI: 10.1007/s00213-013-3003-2.
[2]  Abbasy S, Shahraki F, Haghighatfard A, et al. Neuregulin1 types mRNA level changes in autism spectrum disorder, and is associated with deficit in executive functions[J]. EBioMedicine, 2018, 37: 483-488. DOI: 10.1016/j.ebiom.2018.10.022.
[3]  郭汝金, 敖丽娟, 李咏梅, 等. 神经调节蛋白1-ErbB信号通路的研究进展[J]. 中国康复医学杂志, 2014, 29(7): 679-684. DOI: 10.3969/j.issn.1001-1242.2014.07.025.
[4] Hashimoto R, Straub RE, Weickert CS, et al. Expression analysis of neuregulin-1 in the dorsolateral prefrontal cortex in schizophrenia[J]. Mol Psychiatry, 2004, 9(3): 299-307. DOI: 10.1038/sj.mp.4001434.
[5] Ikawa D, Makinodan M, Iwata K, et al. Microglia-derived neuregulin expression in psychiatric disorders[J]. Brain Behav Immun, 2017, 61: 375-385. DOI: 10.1016/j.bbi.2017.01.003.
[6] Deakin IH, Nissen W, Law AJ, et al. Transgenic overexpression of the type I isoform of neuregulin 1 affects working memory and hippocampal oscillations but not long-term potentiation[J]. Cereb Cortex, 2012, 22(7): 1520-1529. DOI: 10.1093/cercor/bhr223.
[7] Guerra S, Chesworth R, Weickert CS, et al. Effects of handling on the behavioural phenotype of the neuregulin 1 type III transgenic mouse model for schizophrenia[J]. Behav Brain Res, 2021, 405: 113166. DOI: 10.1016/j.bbr.2021.113166.
[8] Esnafoglu E. Levels of peripheral Neuregulin 1 are increased in non-medicated autism spectrum disorder patients[J]. J Clin Neurosci, 2018, 57: 43-45. DOI: 10.1016/j.jocn.2018.08.043.
[9] Olaya JC, Heusner CL, Matsumoto M, et al. Schizophrenia-relevant behaviours of female mice overexpressing neuregulin 1 type III[J]. Behav Brain Res, 2018, 353: 227-235. DOI: 10.1016/j.bbr.2018.03.026.
[10] Naaijen J, Bralten J, Poelmans G, et al. Glutamatergic and GABAergic gene sets in attention-deficit/hyperactivity disorder: association to overlapping traits in ADHD and autism[J]. Transl Psychiatry, 2017, 7(1): e999. DOI: 10.1038/tp.2016.273.
[11] Guan YF, Wu CY, Fang YY, et al. Neuregulin 1 protects against ischemic brain injury via ErbB4 receptors by increasing GABAergic transmission[J]. Neuroscience, 2015, 307: 151-159. DOI: 10.1016/j.neuroscience.2015.08.047.
[12] Hoshino C, Konno A, Hosoi N, et al. GABAergic neuron-specific whole-brain transduction by AAV-PHP.B incorporated with a new GAD65 promoter[J]. Mol Brain, 2021, 14(1): 33. DOI: 10.1186/s13041-021-00746-1.
[13] Dabbah-Assadi F, Alon D, Golani I, et al. The influence of immune activation at early vs late gestation on fetal NRG1-ErbB4 expression and behavior in juvenile and adult mice offspring[J]. Brain Behav Immun, 2019, 79: 207-215. DOI: 10.1016/j.bbi.2019.02.002.
[14] Rahman-Enyart A, Lai C, Prieto AL. Neuregulins 1, 2, and 3 promote early neurite outgrowth in ErbB4-expressing cortical GABAergic interneurons[J]. Mol Neurobiol, 2020, 57(8): 3568-3588. DOI: 10.1007/s12035-020-01966-7.
[15] Deng W, Luo F, Li BM, et al. NRG1-ErbB4 signaling promotes functional recovery in a murine model of traumatic brain injury via regulation of GABA release[J]. Exp Brain Res, 2019, 237(12): 3351-3362. DOI: 10.1007/s00221-019-05680-2.
[16] Maier S, Düppers AL, Runge K, et al. Increased prefrontal GABA concentrations in adults with autism spectrum disorders[J]. Autism Res, 2022, 15(7): 1222-1236. DOI: 10.1002/aur.2740.
[17] Rojas DC. The role of glutamate and its receptors in autism and the use of glutamate receptor antagonists in treatment[J]. J Neural Transm (Vienna), 2014, 121(8): 891-905. DOI: 10.1007/s00702-014-1216-0.
[18] Pearson G, Song C, Hohmann S, et al. DNA methylation profiles of GAD1 in human cerebral organoids of autism indicate disrupted epigenetic regulation during early development[J]. Int J Mol Sci, 2022, 23(16): 9188. DOI: 10.3390/ijms23169188.
[19] Yehia L, Ni Y, Sadler T, et al. Distinct metabolic profiles associated with autism spectrum disorder versus cancer in individuals with germline PTEN mutations[J]. NPJ Genom Med, 2022, 7(1): 16. DOI: 10.1038/s41525-022-00289-x.
[20] Shin S, Santi A, Huang S. Conditional Pten knockout in parvalbumin- or somatostatin-positive neurons sufficiently leads to autism-related behavioral phenotypes[J]. Mol Brain, 2021, 14(1): 24. DOI: 10.1186/s13041-021-00731-8.
[21] Wohr M, Orduz D, Gregory P, et al. Lack of parvalbumin in mice leads to behavioral deficits relevant to all human autism core symptoms and related neural morphofunctional abnormalities[J]. Transl Psychiatry, 2015, 5(3): e525. DOI: 10.1038/tp.2015.19.
[22] Soghomonian JJ, Zhang K, Reprakash S, et al. Decreased parvalbumin mRNA levels in cerebellar Purkinje cells in autism[J]. Autism Res, 2017, 10(11): 1787-1796. DOI: 10.1002/aur.1835.
[23] Bolívar S, Navarro X, Udina E. Schwann cell role in selectivity of nerve regeneration[J]. Cells, 2020, 9(9): 2131. DOI: 10.3390/cells9092131.
[24] Asirvatham AL, Schworer CM, Stahl R, et al. Role of A-kinase anchoring proteins in cyclic-AMP-mediated Schwann cell proliferation[J]. Cell Signal, 2021, 83: 109977. DOI: 10.1016/j.cellsig.2021.109977.
[25] Nave KA, Salzer JL. Axonal regulation of myelination by neuregulin 1[J]. Curr Opin Neurobiol, 2006, 16(5): 492-500. DOI: 10.1016/j.conb.2006.08.008.
[26] Steinman G. The putative etiology and prevention of autism[J]. Prog Mol Biol Transl Sci, 2020, 173: 1-34. DOI: 10.1016/bs.pmbts.2020.04.013.
[27] Malara M, Lutz AK, Incearap B, et al. SHANK3 deficiency leads to myelin defects in the central and peripheral nervous system[J]. Cell Mol Life Sci, 2022, 79(7): 371. DOI: 10.1007/s00018-022-04400-4.
[28] Chen B, Linke A, Olson L, et al. Cortical myelination in toddlers and preschoolers with autism spectrum disorder[J]. Dev Neurobiol, 2022, 82(3): 261-274. DOI: 10.1002/dneu.22874.
[29] Zhang Y, Pang Y, Feng W, et al. miR-124 regulates early isolation-induced social abnormalities via inhibiting myelinogenesis in the medial prefrontal cortex[J]. Cell Mol Life Sci, 2022, 79(9): 507. DOI: 10.1007/s00018-022-04533-6.